Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00206141 |
This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to 52 with quetiapine fumarate (Seroquel) compared to placebo.
Condition | Intervention | Phase |
---|---|---|
Bipolar Disorder Bipolar Depression Depression |
Drug: Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | AstraZeneca Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1447C00001, EMBOLDEN I |
Study First Received: | September 13, 2005 |
Last Updated: | July 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00206141 |
Health Authority: | United States: Food and Drug Administration; Ukraine: Ministry of Health |
Bipolar disorder bipolar depression depression |
Quetiapine Affective Disorders, Psychotic Depression Mental Disorders Bipolar Disorder Mood Disorders |
Lithium Carbonate Psychotic Disorders Depressive Disorder Lithium Behavioral Symptoms |
Tranquilizing Agents Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |